Clinical Trials Logo

CD7+ Lymphoma clinical trials

View clinical trials related to CD7+ Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04599556 Recruiting - CD7+ Lymphoma Clinical Trials

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

This is a prospective, open-label, single-center clinical trial. This study will evaluate the safety and efficacy of anti-CD7 CAR-T cells in the treatment of relapsed or refractory CD7 positive T-ALL/LBL, T-NHL and AML. The primary endpoints are dose limiting toxicity (DLT) and the incidence of treatment emergent adverse event (TEAE).